Comparative efficacy of tegoprazan versus esomeprazole/sodium bicarbonate for the treatment of Helicobacter pylori infectionopen access
- Authors
- Park, Chan Hyuk; Park, Jung Ho; Jung, Yoon Suk
- Issue Date
- Nov-2023
- Publisher
- Nature Publishing Group
- Keywords
- eradication; esomeprazole/sodium bicarbonate; Helicobacter pylori; P-CAB; tegoprazan
- Citation
- Clinical and Translational Gastroenterology, v.14, no.11, pp 1 - 9
- Pages
- 9
- Indexed
- SCIE
SCOPUS
- Journal Title
- Clinical and Translational Gastroenterology
- Volume
- 14
- Number
- 11
- Start Page
- 1
- End Page
- 9
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/197014
- DOI
- 10.14309/ctg.0000000000000632
- ISSN
- 2155-384X
2155-384X
- Abstract
- Introduction:Potassium-competitive acid blockers and proton pump inhibitors/sodium bicarbonate can rapidly increase intragastric pH. Herein, we aimed to compare the clinical outcomes of tegoprazan-based and esomeprazole/sodium bicarbonate-based triple therapies in the treatment of H. pylori infection.
Methods:We retrospectively reviewed the data of patients with H. pylori infection treated with a 14-day tegoprazan-based triple therapy or 14-day esomeprazole/sodium bicarbonate-based triple therapy. The primary endpoint was the H. pylori eradication rate with first-line treatment in an intention-to-treat (ITT) analysis. Secondary endpoints included the eradication rate with first-line therapy in the per-protocol (PP) analysis and adverse events associated with eradication therapy
Results:Of the 854 included patients, 435 were treated with tegoprazan-based therapy and 419 received esomeprazole/sodium bicarbonate-based therapy. In the ITT population, no significant difference in eradication rate was detected between the tegoprazan- and esomeprazole/sodium bicarbonate-treated groups (78.6% [95% confidence interval (CI), 74.6-82.3%] vs. 81.4% [95% CI, 77.4-84.9%], P = 0.313). The PP analysis also revealed a similar eradication rate between groups (tegoprazan vs. esomeprazole/sodium bicarbonate: 85.5% [95% CI, 81.8-87.5%] vs. 87.8% [95% CI, 84.1-90.7%], P = 0.339). However, abdominal discomfort and diarrhea were more common in the esomeprazole/sodium bicarbonate group than in the tegoprazan group (abdominal discomfort: 1.1% vs. 3.8%, P = 0.012; diarrhea: 9.9% vs. 21.2%, P < 0.001)
Discussion:The efficacy of the esomeprazole/sodium bicarbonate-based triple therapy for H. pylori eradication was comparable with that of the tegoprazan-based triple therapy. However, esomeprazole/sodium bicarbonate-based therapy exhibited a higher risk for abdominal discomfort and diarrhea than tegoprazan-based therapy.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.